


NEW INJECTION
FROM SEARLE



In arrhythmias

NORPACE


Disopyramide Phosphate

A SEARLE DISCOVERY

Now you can start as you mean to go on

New Norpace intravenous injection effectively controls a broad spectrum of acute arrhythmias, including ventricular premature contractions, ventricular tachycardia, atrial premature contractions, and atrial tachycardia.

New Norpace injection is presented in two convenient ampoule sizes of 100 and 150mg.




Norpace capsules provide effective and reliable long-term control.

Norpace capsules are also presented in two strengths for greater flexibility of dosage, ensuring adequate serum levels with a q.i.d. regimen in the majority of patients.

SLOW-TRASICOR[®] in

160 mg oxprenolol hydrochloride BP in a sustained-release formulation



The once daily treatment

Prescribing Notes:

Presentation Slow-Trasicor tablets each contain 160mg oxprenolol hydrochloride BP in a special sustained-release formulation available in simple daily reminder packs of 28 tablets. **Dosage in hypertension** Initially one or two tablets in the morning. **Dosage in angina** Initially one or two tablets in the morning. An evening dose may be beneficial in nocturnal angina. As with other beta-blocking drugs, sudden withdrawal of treatment may induce severe and continuous angina. Patients should, therefore, be advised to avoid interruption of established therapy and if withdrawal becomes necessary it should be done gradually. **Side effects** Dizziness, drowsiness, headache, insomnia, excitement and gastro-intestinal disturbance may occur and, rarely, isolated cases of excessive bradycardia. Beta-blockers are occasionally associated with skin rashes and/or dry eyes. If any such reaction is suspected, treatment should be withdrawn gradually. **Precautions** If there is evidence of cardiac failure this must be controlled by digitalis and/or diuretics before and during Slow-Trasicor therapy. Should the pulse rate fall below 50 per minute, then treatment should be restarted at a lower dose. Caution should be observed when treating asthmatics, chronic bronchitics or other individuals where bronchospasm may be provoked. Slow-Trasicor should be given cautiously to patients with alcoholism, metabolic acidosis, during pregnancy or anaesthesia with ether or chloroform. Beta-blockers can mask symptoms of hypoglycaemia and also affect carbohydrate metabolism. It may therefore be necessary to readjust the insulin requirements in diabetic patients. Occasionally hypotension may occur with higher dose levels. **Contra-indications** Patients with atrio-ventricular block, marked bradycardia and cardiogenic shock. **Packs** Cartons of 28 Slow-Trasicor tablets consisting of two reminder calendar foils of 14. Basic NHS price £6.66 PL0008 0130 PA 28 7 1 Full prescribing information is available on request from CIBA Laboratories, Horsham, West Sussex. [®] denotes registered trademark.

C I B A



**In
hypertension...**

**add
Hypovase**

**a logical combination with
a beta-blocker or a diuretic**

- Hypovase produces a relaxation of arteriolar smooth muscle, lowering elevated blood pressure by reducing total peripheral resistance.
- Produces an *additive effect* when combined with a beta-blocker or with a thiazide diuretic.¹
- No significant effect on cardiac index, heart rate or stroke index² . . . the incidence of tachycardia is negligible.^{3,4,5,6}
- May be administered to hypertensive patients with diabetes, bronchial asthma, gout, alcoholism, or renal failure.¹

Hypovase*
brand of prazosin hydrochloride

Indications: hypertension of varied aetiology and all grades of severity. Contraindications: sensitivity to Hypovase. Precautions: a small percentage of patients may react more rapidly and to a greater extent than the majority; in some cases this has led to sudden loss of consciousness generally lasting a few minutes. Subsequent treatment may be satisfactory. Hypovase is not recommended in pregnancy, during lactation, or in children under 12 years of age. Side effects: dizziness, drowsiness and lack of energy are the most common. Dosage: starting dose 0.5mg two to three hours before retiring; thereafter, range 1.5 to 20mg/day in divided doses. Basic N.H.S. Cost: Initial Treatment Pack containing 22 x 0.5mg Hypovase tablets (PL57/0149) and 21 x 1mg Hypovase tablets, £2.40. 1mg tablet (PL57/0106), pack of 100, £4.68; 2mg tablet (PL57/0107), pack of 100, £6.12; 5mg tablet (PL57/0108), pack of 100, £13.26. Full information on request.

References: 1. *Cardiovascular Medicine*, Jan. 1978, p. 45 (41-56), Vol. 3, No. 1. 2. *Drugs* (review article), 1977, 14, 163-197. 3. *Postgraduate Medicine*, Nov. 1975, p. 117-127. 4. *Circulation*, 1968, 38, 164. 5. Proceedings of a Symposium held at the Centre Interprofessionnel, Geneva, 8th March, 1974. 6. *Drugs* (review article), 1977,

Cambridge Medical

Echocardiograms

+ Phonocardiograms

**+ Pressure
measurements**

+ ECGs


+ Respiration

+ Pulse

+ Quality recording

+ Proven reliability

+ Cambridge service



**= Cambridge MCPR
Cardiac Diagnostic System**

**Cambridge Medical
Instruments Limited**

Melbourn Royston
Herts SG8 6EJ England
Tel. Royston (0763) 60611
Telex 81124